These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 18648370)

  • 1. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance.
    Lo M; Ling V; Wang YZ; Gout PW
    Br J Cancer; 2008 Aug; 99(3):464-72. PubMed ID: 18648370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.
    Pham AN; Blower PE; Alvarado O; Ravula R; Gout PW; Huang Y
    J Pharmacol Exp Ther; 2010 Mar; 332(3):949-58. PubMed ID: 20007406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer.
    Lo M; Ling V; Low C; Wang YZ; Gout PW
    Curr Oncol; 2010 Jun; 17(3):9-16. PubMed ID: 20567622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target.
    Albrecht P; Lewerenz J; Dittmer S; Noack R; Maher P; Methner A
    CNS Neurol Disord Drug Targets; 2010 Jul; 9(3):373-82. PubMed ID: 20053169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc
    Guo W; Li K; Sun B; Xu D; Tong L; Yin H; Liao Y; Song H; Wang T; Jing B; Hu M; Liu S; Kuang Y; Ling J; Li Q; Wu Y; Wang Q; Yao F; Zhou BP; Lin SH; Deng J
    Cancer Res; 2021 Feb; 81(3):552-566. PubMed ID: 33229341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
    Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.
    Bhutia YD; Hung SW; Patel B; Lovin D; Govindarajan R
    Cancer Res; 2011 Mar; 71(5):1825-35. PubMed ID: 21343396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer.
    Fan J; Wei Q; Koay EJ; Liu Y; Ning B; Bernard PW; Zhang N; Han H; Katz MH; Zhao Z; Hu Y
    Theranostics; 2018; 8(21):5986-5994. PubMed ID: 30613276
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
    Fryer RA; Barlett B; Galustian C; Dalgleish AG
    Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. System χ
    Yoo S; Bae JY; Moon J; Koh G
    Free Radic Biol Med; 2020 Jun; 153():17-25. PubMed ID: 32305647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.
    Li J; Zhu J; Melvin WS; Bekaii-Saab TS; Chen CS; Muscarella P
    J Gastrointest Surg; 2006 Feb; 10(2):207-14. PubMed ID: 16455452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells.
    Thomas AG; Sattler R; Tendyke K; Loiacono KA; Hansen H; Sahni V; Hashizume Y; Rojas C; Slusher BS
    PLoS One; 2015; 10(8):e0127785. PubMed ID: 26252954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
    Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M
    Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
    Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
    Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
    Arumugam T; Ramachandran V; Fournier KF; Wang H; Marquis L; Abbruzzese JL; Gallick GE; Logsdon CD; McConkey DJ; Choi W
    Cancer Res; 2009 Jul; 69(14):5820-8. PubMed ID: 19584296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death.
    Banjac A; Perisic T; Sato H; Seiler A; Bannai S; Weiss N; Kölle P; Tschoep K; Issels RD; Daniel PT; Conrad M; Bornkamm GW
    Oncogene; 2008 Mar; 27(11):1618-28. PubMed ID: 17828297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.